Skip to content

evaluation of cardiovascular properties of Different Anesthetic Agents in root canal Therapy

The Hemodynamic Properties of Different Anesthetic Agents in Endodontic Therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014011316210N1
Enrollment
80
Registered
2014-04-13
Start date
2010-10-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endodontic treatment.

Interventions

Intervention 1: inferior alveolar nerve block using one cartridge of Lidocaine 2% + Epinephrine 1: 80000 in 7 stages. Intervention 2: inferior alveolar nerve block using one cartridge of Prilocaine3
Treatment - Drugs
inferior alveolar nerve block using one cartridge of Lidocaine 2% + Epinephrine 1: 80000 in 7 stages
inferior alveolar nerve block using one cartridge of Prilocaine3% +0.03 IU/ml felypressin in 7 stages
inferior alveolar nerve block using one cartridge of Articaine 4% + Epinephrine 1: 100000in 7 stages
inferior alveolar nerve block using one cartridge of Mepivacaine 3% in 7 stages
The participants in each group by measurments before internention are themselves control.

Sponsors

Zahedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: having heaith and at least one mandibular molar or premolar painful tooth; requiring endodontic therapy on the side of injection. Exclusion criteria: patients reporting history of any systemic condition; history of any drug in last wee; pregnancy and anxiety.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Heart rate. Timepoint: Stage 1: Upon entrance into the office, Stage 2: 15 minutes after the patient was seated, Stage 3: immediately before the injection, Stages 4-7: immediately, 5, 10 and 15 minutes after the injection. Method of measurement: a monitoring device (1800, Saadat).;Arythmia. Timepoint: Stage 1: Upon entrance into the office, Stage 2: 15 minutes after the patient was seated, Stage 3: immediately before the injection, Stages 4-7: immediately, 5, 10 and 15 minutes after the injection. Method of measurement: a monitoring device (1800, Saadat).;Systolic blood pressure. Timepoint: Stage 1: Upon entrance into the office, Stage 2: 15 minutes after the patient was seated, Stage 3: immediately before the injection, Stages 4-7: immediately, 5, 10 and 15 minutes after the injection. Method of measurement: a monitoring device (1800, Saadat).;Diastolic blood pressure. Timepoint: Stage 1: Upon entrance into the office, Stage 2: 15 minutes after the patient was seated, Stage 3: immediately before the injection, Stages 4-7: immediately, 5, 10 and 15 minutes after the injection. Method of measurement: a monitoring device (1800, Saadat).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarahnaz Dadgar

Zahedan University of Medical Sciences

dr.dadgar@zaums.ac.ir; frhnzddgr@gmail.com+98 54 1241 2005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026